Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003003 · ClinicalTrials.gov registry record · Phase 1
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00003003 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT00003003, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
Interventions
- BIOLOGICAL sargramostim
- DRUG mitoxantrone hydrochloride
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1996-09 |
| Est. Completion | 2000-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003003
The ClinicalTrials.gov registry entry for NCT00003003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00003003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003003 about?
NCT00003003 is a clinical study titled "Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPO...
What is the current status of trial NCT00003003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 1996-09. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00003003?
The interventions under investigation include: sargramostim (BIOLOGICAL), mitoxantrone hydrochloride (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00003003?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.